ArticleThe British journal of dermatology2023

Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.

William D Shipman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.